CA2336879C — Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
Assigned to Virbac Australia Pty Ltd · Expires 2010-06-01 · 16y expired
What this patent protects
A pharmaceutical and/or veterinary formulation comprising about 2-30 %(w/w) (on an active basis) of at least one active agent, about 0.5-20.0 %(w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in hu…
USPTO Abstract
A pharmaceutical and/or veterinary formulation comprising about 2-30 %(w/w) (on an active basis) of at least one active agent, about 0.5-20.0 %(w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.